Inotiv, Inc.

Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Inotiv, Inc. reports robust Q4 earnings, eyes sales growth opportunities

Inotiv, Inc. delivered strong financial performance in Q4 2022, with a focus on revenue growth and margin enhancement. Despite challenges in the NHP business and operational disruptions, the company remains optimistic about future prospects and anticipates significant sales growth from recent price increases.

Inotiv reports robust revenue growth in Q1 2023 earnings call

Inotiv Inc. demonstrated strong revenue growth in Q1 2023, despite facing challenges with negative adjusted EBITDA. The company's focus on cost reductions, pricing increases, and operational enhancements presents opportunities for future growth. Inotiv remains optimistic about its future prospects, having made tough decisions to improve its performance.

Inotiv reports revenue growth and EBITDA improvement, faces guidance challenges

Inotiv's Q2 showed revenue growth and EBITDA improvement, driven by DSA and RMS segments. Despite challenges with increased expenses and guidance adjustments, the company remains focused on margin improvements, supplier vetting, and investor engagement.

Inotiv reports robust Q3 earnings amidst NHP supply challenges

Inotiv's Q3 2023 earnings call highlighted strong financial performance, strategic initiatives, and challenges related to NHP supply.
The company's focus on operational optimization, cost reduction, and growth opportunities underscores a commitment to sustainable expansion.
Despite industry challenges, Inotiv remains confident in achieving long-term EBITDA margins of 18-22% and is actively addressing supply chain issues.
Proactive measures to manage NHP supply challenges and explore revenue growth opportunities position Inotiv for continued success in the CRO industry.

Inotiv reports robust fiscal 2023 performance and strategic growth outlook

Inotiv's strong fiscal performance in 2023 and strategic initiatives position the company for continued growth and operational excellence in 2024.
While challenges in the NHP market and uncertainties in certain service segments exist, Inotiv's focus on innovation and efficiency mitigates potential risks.
Opportunities for revenue growth through service expansion, cost reductions, and customer relationship enhancement underscore a positive outlook for the company.
By leveraging strengths in operational efficiency, service quality, and market positioning, Inotiv aims to solidify its position as a leading CRO provider and drive sustainable growth.

Inotiv reports strong Q1 results, eyes growth through acquisitions

Inotiv's Q1 performance reflects positive momentum with revenue growth and improved profitability. The company's strategic focus on operational efficiency, acquisitions, and expansion sets the stage for future success. Challenges lie in sustaining growth through effective cost management and operational optimization.

Inotiv reports mixed Q4 results, eyes growth in NHP services

Inotiv's Q4 performance showed revenue growth but faced challenges from industry dynamics. The company is optimistic about growth opportunities in NHPs and other services, with a focus on margin improvements and customer base expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024.

Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Inotiv, Inc. Launches Proposed Public Offering of Common Shares

Inotiv, Inc. (NASDAQ:NOTV ) Q4 2024 Earnings Conference Call December 3, 2024 4:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Operator Good day, everyone, and welcome to today's Inotiv Fiscal 2024 Fourth Quarter Financial Results. At this time, all participants are in a listen-only mode.

Inotiv, Inc. (NOTV) Q4 2024 Earnings Call Transcript

—  Enhanced liquidity through issuance of Second Lien Notes —  Obtained amendment to credit agreement and extended note payable —  Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million —  Full year fiscal 2024 revenue down 14.3% to $490.7 million —  Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2024”) and twelve months ("FY 2024") ended September 30, 2024.

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update

Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth

Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market.

Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024

WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering.

Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity

WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., Inotiv's President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the 8th Annual Lake Street Best Ideas Growth Conference on Thursday, September 12, 2024, in New York City.

Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference

Inotiv, Inc. (NASDAQ:NOTV ) Q3 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Eric Coldwell - Baird Operator Good day, everyone and welcome to this Inotiv Third Quarter Earnings Conference Call. [Operator Instructions] And it's now my pleasure to turn the floor over to Mr.

Inotiv, Inc. (NOTV) Q3 2024 Earnings Call Transcript

Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.07 per share a year ago.

Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates

WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024

Daqo New Energy

Symbotic Inc

In the current volatile market, breakout stocks with sound growth potential are most important for those investors looking to maximize returns. The list includes three such standout companies that can deliver substantial gains.

3 Breakout Stocks to Buy Before They Make Headlines

Nkarta, Inc.

Rapid7

For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan.

3 Undervalued Stocks Primed for a 2X Return

WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates:

Inotiv, Inc. Provides Business Updates

Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare

Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility

WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference.

Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV). The investigation concerns whether Inotiv and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On May 13, 2024, Inotiv disclosed that it is unable to timely file its Quarterly Report on Form 10-Q for the quarter e.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Inotiv, Inc. (NOTV)

Inotiv, Inc. (NASDAQ:NOTV ) Q2 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and CEO Beth Taylor - Chief Financial Officer Conference Call Participants Dave Windley - Jefferies Matt Hewitt - Craig-Hallum Frank Takkinen - Lake Street Capital Markets Operator Good afternoon ladies and gentlemen and welcome to the Inotiv's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Inotiv, Inc. (NOTV) Q2 2024 Earnings Call Transcript

— Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on related matter— Site optimization projects near completion— Conference call begins today at 4:30 pm ET

Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update

Inotiv (NASDAQ: NOTV ) stock is down on Tuesday after the drug discovery and development services company reported preliminary results for Q1 2024. This has the company noting that its revenue for the six months ended on March 31, 2024 will be $254.5 million.

Why Is Inotiv (NOTV) Stock Down 35% Today?

WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Wednesday, May 15, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024

WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the release of the Company's financial results for the three and six months ended March 31, 2024 and the conference call to discuss the results that were originally scheduled for Friday, May 10, 2024 are being rescheduled to provide the Company additional time to complete the accounting analyses related to certain matters. Specifically, as previously disclosed, the Company has been cooperating with the U.S. Department of Justice (the “DOJ”) and other authorities related to an investigation by those authorities into various matters relating to the previously disclosed execution of a search and seizure warrant at the Company's Cumberland, Virginia facility. Due to the current status of negotiations between the Company and the DOJ regarding a potential resolution, as well as related actions that would need to occur in order for any such resolution to be finalized, including, without limitation, negotiations between the Company and DOJ regarding mutually satisfactory resolution documents, final approvals by DOJ and the Company, and depending on the terms of any final resolution with the DOJ, negotiations with certain of the Company's stakeholders regarding the feasibility of such proposed resolution, the Company requires additional time to complete the analysis of this subsequent event and the related accounting matters. The Company is working diligently to complete these analyses and finalize its financial statements as soon as possible.

Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inotiv, Inc. (NasdaqCM: NOTV). On November 5, 2021, the Company completed its purchase of Envigo RMS, LLC (“Envigo”) after several months of discussion and due diligence reviews. However, from July 2021 onward, Envigo's Cumberland Facility had been charged with numerous serious violati.

INOTIV INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV

WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Friday, May 10, 2024, before the opening of the stock market. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results.

Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024

NEW ORLEANS, La. , April 19, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

INOTIV INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inotiv, Inc. - NOTV

News for Inotiv, Inc. Stock (NOTV)